Cargando…

Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report

Alpelisib plus fulvestrant is a valid second or advanced line of treatment for patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who harbor an activating PIK3CA mutation. The well-known side effects of alpelisib are hyperglycemia, rash, and diarrhea. Herein, we rep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hinich, Maayan Geller, Hijab, Adham
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642942/ https://www.ncbi.nlm.nih.gov/pubmed/37965451 http://dx.doi.org/10.3389/fonc.2023.1255832

Ejemplares similares

Acrofacial Vitiligo Following Halo Formation around Congenital Melanocytic Naevi
por: Gupta, Lalit Kumar, et al.
Publicado: (2016)

Case report: Alpelisib-induced Stevens–Johnson syndrome
por: Kurian, Christine Jane, et al.
Publicado: (2022)

A Case Report: Nager Acrofacial Dysostosis
por: Abdollahi Fakhim, Shahin, et al.
Publicado: (2012)

The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer
por: Cataldo, Maria Letizia, et al.
Publicado: (2023)

Orodental findings in postaxial acrofacial dysostosis
por: Urs, Aadithya B, et al.
Publicado: (2014)

Acrofacial necrotic ulcers in an infant: An undiagnosed presentation
por: Sarika, Georgina-Maria, et al.
Publicado: (2022)

Limbal dermoid in Nager acrofacial dysostosis: A rare case report
por: Malik, Rohit, et al.
Publicado: (2014)

PI3KCA Mutations in Uterine Cervix Carcinoma
por: Voutsadakis, Ioannis A.
Publicado: (2021)

Dental Management of a Patient with Nager Acrofacial Dysostosis
por: Bozatlıoğlu, R., et al.
Publicado: (2015)

MON-LB128 Phosphoinositide 3-Kinase (PI3K) Inhibitor Induced Hyperglycemia With Alpelisib
por: Barsukova, Yuliya, et al.
Publicado: (2020)

The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer
por: Passarelli, Anna, et al.
Publicado: (2023)

Case Report: Alpelisib-Induced Drug Reaction With Eosinophilia and Systemic Symptoms: A Rare Manifestation of a Common Side Effect
por: Majeed, Umair, et al.
Publicado: (2021)

Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
por: Tankova, Tsvetalina, et al.
Publicado: (2022)

Acquired Speckled Acrofacial Hypomelanosis: A Novel Presentation of an Existing Dermatosis
por: Singh, Ajeet, et al.
Publicado: (2022)

P1122: EFFICACY OF ALPELISIB IN PI3K-DRIVEN LANGERHANS CELL HISTIOCYTOSIS
por: Mazor, R., et al.
Publicado: (2022)

A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies
por: Tsang, Erica S., et al.
Publicado: (2022)

The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells
por: Kirstein, Anna S., et al.
Publicado: (2019)

MDM2 Amplification and PI3KCA Mutation in a Case of Sclerosing Rhabdomyosarcoma
por: Kikuchi, Ken, et al.
Publicado: (2013)

Novel Phenolic Inhibitors of Small/Intermediate-Conductance Ca(2+)-Activated K(+) Channels, KCa3.1 and KCa2.3
por: Oliván-Viguera, Aida, et al.
Publicado: (2013)

Diabetic Ketoacidosis With Alpelisib
por: Jeun, Rebecca, et al.
Publicado: (2021)

Alpelisib for breast cancer
Publicado: (2022)

Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease
por: Jin, Lee‐Way, et al.
Publicado: (2019)

Efficacy of Providing the PI3K p110α Inhibitor BYL719 (Alpelisib) to Middle-Aged Mice in Their Diet
por: Hedges, Christopher P., et al.
Publicado: (2021)

Alpelisib-Induced Diabetic Ketoacidosis- A Case Report
por: Rodriguez, Lisette Patricia, et al.
Publicado: (2021)

Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience
por: Alaklabi, Sabah, et al.
Publicado: (2022)

Contribution of the KCa3.1 channel–calmodulin interactions to the regulation of the KCa3.1 gating process
por: Morales, Patricia, et al.
Publicado: (2013)

Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an N-of-1 clinical trial
por: Shaheen, Montaser F, et al.
Publicado: (2022)

A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma
por: Shoushtari, Alexander N., et al.
Publicado: (2021)

Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors
por: Ando, Yuichi, et al.
Publicado: (2019)

Alpelisib-Induced Diabetic Ketoacidosis
por: Espinosa, Luis Borges, et al.
Publicado: (2021)

Alpelisib-Induced Diabetic Ketoacidosis
por: Nguyen, Paul, et al.
Publicado: (2021)

Low Voltage Activation of KCa1.1 Current by Cav3-KCa1.1 Complexes
por: Rehak, Renata, et al.
Publicado: (2013)

Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
por: Shaker, Mohamed E., et al.
Publicado: (2023)

AcSDKP Regulates Cell Proliferation through the PI3KCA/Akt Signaling Pathway
por: Hu, Ping, et al.
Publicado: (2013)

PMON01 Alpelisib (PI3-K Inhibitor) Induced Severe Insulin Resistance Complicated by Diabetic Ketoacidosis (DKA) with Rapid Reversal Following Discontinuation: A Case Report
por: Lloyd, Jacob, et al.
Publicado: (2022)

PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer
por: Kim, Kui-Jin, et al.
Publicado: (2020)

Corrigendum: Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
por: Shaker, Mohamed E., et al.
Publicado: (2023)

Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery
por: Derbel, Olfa, et al.
Publicado: (2013)

Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature
por: Carrillo, Maritza, et al.
Publicado: (2020)

Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations
por: Pla Peris, Begoña, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3tn05oaj7k6rmk6jmav9omo7fi